Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 3/20 | 0.57 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4199626 | 0.89 | HTR6 (0.62) | HTR6QRFPRKMT2AALDH1A1MAPK1 | |
| SCHEMBL4206759 | 0.87 | HTR6 (0.60) | HTR6QRFPRKMT2AALDH1A1MAPK1 | |
| SCHEMBL4196211 | 0.87 | LMNA (0.56) | HTR6QRFPRKMT2AALDH1A1MAPK1 | |
| SCHEMBL4200847 | 0.86 | HTR6 (0.62) | HTR6QRFPRKMT2AALDH1A1LMNA | |
| SCHEMBL4199323 | 0.86 | HTR6 (0.52) | HTR6QRFPRKMT2AMAPK1LMNA | |
| SCHEMBL4212808 | 0.85 | HTR6 (0.61) | HTR6QRFPRKMT2AALDH1A1MAPK1 | |
| SCHEMBL4203089 | 0.84 | KMT2A (0.49) | HTR6QRFPRKMT2AALDH1A1MAPK1 | |
| SCHEMBL4204559 | 0.84 | HTR6 (0.68) | HTR6QRFPRKMT2AALDH1A1MAPK1 | |
| SCHEMBL4209393 | 0.83 | HTR6 (0.67) | HTR6QRFPRKMT2AALDH1A1MAPK1 | |
| SCHEMBL4967095 | 0.83 | HTR6 (0.60) | HTR6QRFPRKMT2AALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030038-A1 | Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | claimed |
| US-20090030038-A1 | Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030038-A1 | Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor | HTR6, HTR1A, HTR1D | HTR6 1/4885QRFPR 81/4885KMT2A 2752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.